Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 11 hours agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 7 days agoOn Friday, Wells Fargo adjusted its outlook on shares of pharmaceutical giant Merck & Co., Inc....
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 1 day agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
mRNA Is Promising A Breakthrough In Fighting Cancer
Benzinga via AOL· 4 days agoWhen it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 22 hours agoLast year, major pharmaceutical companies heavily invested in R&D, with expenditure ranging from around 14% to 50% of their revenues. Some of the...
Merck KGaA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 4 days agoMerck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29. As investors...
Cantor Fitzgerald Brokers Boost Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)
ETF DAILY NEWS· 3 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 14 hours agoThe company usually earns collaboration revenues from agreements with several big pharma/biotech...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 4 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Earnings call: Daiichi Sankyo posts strong FY 2023 results, plans growth
Investing.com· 4 days agoThe pharmaceutical company's strong performance was primarily driven by robust sales of its key...